Levine Leichtman Capital Partners portfolio company Monte Nido & Affiliates acquires Walden Behavioral Care
Monte Nido & Affiliates (Monte Nido), a portfolio company of Levine Leichtman Capital Partners (LLCP), has completed its acquisition of Walden Behavioral Care (Walden). Monte Nido is one of the USA's most established eating disorder treatment providers.
Founded in 2003 and based in Waltham, Massachusetts, Walden is an industry pioneer, offering inpatient, residential, partial hospitalisation and intensive outpatient programmes in Massachusetts, Connecticut and Georgia. Walden opened the Walden Behavioral Care Center for Recovery in 2020, one of the largest 24-hour inpatient and residential care facilities dedicated to the treatment of eating disorders in the US.
Headquartered in Miami, Florida and now operating 44 facilities across thirteen states, Monte Nido & Affiliates has established a track record of clinical excellence, successfully treating adult and adolescent patients since its founding in 1996. The acquisition of Walden expands Monte Nido’s inpatient service offering, further enhancing its comprehensive continuum of care. Monte Nido & Affiliates now offers inpatient, residential and outpatient services through five brands: Monte Nido, Oliver-Pyatt Centers, Clementine, Rosewood and Walden.
Stuart Koman, PhD, Founder and Chief Executive Officer of Walden, has been appointed Chief Strategy Officer of Monte Nido & Affiliates.
Candy Henderson, MS, CEO of Monte Nido & Affiliates, says: “We are thrilled to welcome Dr Koman and the entire Walden team of dedicated professionals to the Monte Nido family of trusted programmes. Walden has provided exceptional eating disorder treatment for almost two decades, and shares Monte Nido’s unwavering commitment to providing the best possible care to our patients, empowering them to realise their healthy selves.”
Matthew Rich, a Senior Managing Director with LLCP, adds: “We are excited to demonstrate our continued support of Candy and the Monte Nido team through this strategic acquisition. The addition of Walden will enable Monte Nido to enhance its continuum of treatment offerings and geographic reach, further solidifying the Company’s position as a market leader.”